Outcomes Associated with Introduction of the 5 Generation High-Sensitivity Cardiac Troponin in Patients Presenting with Cardiovascular Disorders.

Background: The new high-sensitivity cardiac troponin T (hs-cTnT) is now widely used in the United States.

Objectives: We aimed to examine outcomes associated with the introduction of the new 5 generation hs-cTnT assay among patients presenting to the emergency department (ED) with cardiovascular (CV) disorders.

Methods: The study comprised 5377 patients presenting to the ED with CV disorders between January and September 2018.

Defining Minimum Necessary Anticoagulation-Related Communication at Discharge: Consensus of the Care Transitions Task Force of the New York State Anticoagulation Coalition.

Background: Anticoagulated patients are particularly vulnerable to ADEs when they experience changes in medical acuity, pharmacotherapy, or care setting, and resources guiding care transitions are lacking. The New York State Anticoagulation Coalition convened a task force to develop a consensus list of requisite data elements (RDEs) that should accompany all anticoagulated patients undergoing care transitions.

Methods: A multidisciplinary panel of 15 anticoagulation experts voluntarily completed an iterative Delphi process.

Present and Future of Interventional Treatment of Resistant Hypertension.

The increasing prevalence of hypertension, a significant cause of disability and premature death throughout the world, is a major public health concern. This is especially true for the subset of patients who suffer from resistant hypertension, which is associated with a fourfold greater risk of cardiovascular events as compared to those hypertensive patients able to achieve target blood pressure. Though quite daunting in number and ill effect, hypertension remains the most common and the most important modifiable risk factor for coronary heart disease, congestive heart failure, peripheral vascular disease, stroke, and chronic kidney disease.

Baroreceptor Stimulation for Resistant Hypertension.

Hypertension (HTN) is a worldwide epidemic. When untreated, HTN places patients at an elevated risk for several health conditions, including cardiovascular disease and end-organ damage. This effect is particularly pronounced in a subset of patients who experience treatment-resistant HTN despite the utilization of conventional medication and lifestyle interventions.

Carotid Baroreceptor Stimulation and Arteriovenous Shunts for Resistant Hypertension.

Pharmacologic therapy for hypertension is effective for the majority of patients with hypertension, but there is a subset of the population with treatment-resistant hypertension who cannot achieve their blood pressure goal despite taking multiple medications. Since these patients are at increased risk of cardiovascular disease and end-organ damage, additional therapies must be considered. This review discusses several novel interventional therapies-including baroreflex activation therapy, baroreceptor stenting, and creation of an arteriovenous shunt-that may provide alternative options for blood pressure control in those with treatment-resistant hypertension.

The Baroreflex in Hypertension.

Hypertension is a complex syndrome that increases the risk of developing other medical comorbidities and interacts with other medical conditions to increase the risk of target end-organ damage such as cardiovascular disease, stroke, and renal disease. Hypertension remains under-recognized and poorly controlled in the USA and worldwide. In some patients, hypertension is resistant to optimal medical therapy.